Literature DB >> 31262497

Nonalcoholic Fatty Liver Disease Is Associated With Arterial Distensibility and Carotid Intima-Media Thickness: (from the Multi-Ethnic Study of Atherosclerosis).

Ebenezer Oni1, Matthew J Budoff2, Irfan Zeb3, Dong Li2, Emir Veledar4, Joseph F Polak5, Ron Blankstein6, Nathan D Wong7, Michael J Blaha8, Arthur Agatston4, Roger S Blumenthal8, Khurram Nasir9.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is considered a potential independent risk factor for cardiovascular disease (CVD). The Multi-Ethnic Study of Atherosclerosis cohort enrolled 6,814 adults without previous CVD. We excluded 2,692 participants who had missing variables, were heavy drinkers, or history of steroid use and/or chronic liver disease. NAFLD was defined using noncontrast cardiac CT and a liver/spleen Hounsfield Unit attenuation ratio <1. Ultrasound-measured carotid arterial compliance and stiffness, was expressed as distensibility coefficient and Young's modulus. Common and internal carotid intima-media thickness (CIMT) and coronary artery calcium (CAC) >0 were used as markers of subclinical CVD. A multivariate robust linear regression and logistic regression analysis were done to evaluate the association of NAFLD and this subclinical CVD markers. Our analysis of 4,123 participants showed 55% were female with a mean age of 63 (±10) years, 39% white, 10% Chinese, 28% black, and 23% were Hispanic. The prevalence of NAFLD was 17% (n = 729). Patients with NAFLD had higher distensibility coefficient and higher CIMT. Multivariate linear regression analysis showed the presence of NAFLD was associated with both the common carotid and internal carotid IMT and logCAC. Logistic analysis showed an independent association with CAC > 0 (odds ratio [OR] 1.44 95% confidence interval [CI] 1.18, 1.75) and CIMT > 1 mm (OR 1.30 95% 1.08, 1.56). When stratified by race the association with CIMT > 1 mm was significant in whites (OR 1.37 95% 1.00, 1.90) and Hispanic (OR 1.53 95% 1.08, 2. 17) and CAC > 0 was significant in Hispanics (OR 1.52 95% 1.06, 2.19). In conclusion, NAFLD is modestly associated with carotid IMT and coronary artery calcification in a multiethnic population.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31262497     DOI: 10.1016/j.amjcard.2019.05.028

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  12 in total

1.  Lipid and saturated fatty acids intake and cardiovascular risk factors of obese children and adolescents.

Authors:  Claudio Maffeis; Margherita Cendon; Francesca Tomasselli; Mara Tommasi; Irene Bresadola; Elena Fornari; Anita Morandi; Francesca Olivieri
Journal:  Eur J Clin Nutr       Date:  2020-12-05       Impact factor: 4.016

2.  Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals.

Authors:  Ansel Shao Pin Tang; Kai En Chan; Jingxuan Quek; Jieling Xiao; Phoebe Tay; Margaret Teng; Keng Siang Lee; Snow Yunni Lin; May Zin Myint; Benjamin Tan; Vijay K Sharma; Darren Jun Hao Tan; Wen Hui Lim; Apichat Kaewdech; Daniel Huang; Nicholas Ws Chew; Mohammad Shadab Siddiqui; Arun J Sanyal; Mark Muthiah; Cheng Han Ng
Journal:  Clin Mol Hepatol       Date:  2022-03-02

Review 3.  Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: The Heart of the Matter.

Authors:  Stefan Chiriac; Carol Stanciu; Irina Girleanu; Camelia Cojocariu; Catalin Sfarti; Ana-Maria Singeap; Tudor Cuciureanu; Laura Huiban; Cristina Maria Muzica; Sebastian Zenovia; Robert Nastasa; Anca Trifan
Journal:  Can J Gastroenterol Hepatol       Date:  2021-01-12

Review 4.  Mechanisms of Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome. A Narrative Review.

Authors:  Luca Rinaldi; Pia Clara Pafundi; Raffaele Galiero; Alfredo Caturano; Maria Vittoria Morone; Chiara Silvestri; Mauro Giordano; Teresa Salvatore; Ferdinando Carlo Sasso
Journal:  Antioxidants (Basel)       Date:  2021-02-10

5.  Association between non-alcoholic fatty liver disease and subclinical atherosclerosis in Western and Asian cohorts: an updated meta-analysis.

Authors:  Mark Yu Zheng Wong; Jonathan Jiunn Liang Yap; Rehena Sultana; Mark Cheah; George Boon Bee Goh; Khung Keong Yeo
Journal:  Open Heart       Date:  2021-12

Review 6.  Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs.

Authors:  Eleftheria Galatou; Elena Mourelatou; Sophia Hatziantoniou; Ioannis S Vizirianakis
Journal:  Antioxidants (Basel)       Date:  2022-05-27

7.  Non-alcoholic steatohepatitis and progression of carotid atherosclerosis in patients with type 2 diabetes: a Korean cohort study.

Authors:  Hyeok-Hee Lee; Yongin Cho; Young Ju Choi; Byung Wook Huh; Byung-Wan Lee; Eun Seok Kang; Seok Won Park; Bong-Soo Cha; Eun Jig Lee; Yong-Ho Lee; Kap Bum Huh
Journal:  Cardiovasc Diabetol       Date:  2020-06-13       Impact factor: 9.951

8.  Alterations of Gut Microbiome and Serum Metabolome in Coronary Artery Disease Patients Complicated With Non-alcoholic Fatty Liver Disease Are Associated With Adverse Cardiovascular Outcomes.

Authors:  Xiaomin Hu; Ruilin Zhou; Hanyu Li; Xinyue Zhao; Yueshen Sun; Yue Fan; Shuyang Zhang
Journal:  Front Cardiovasc Med       Date:  2022-01-03

Review 9.  Dysregulated lipid metabolism links NAFLD to cardiovascular disease.

Authors:  Audrey Deprince; Joel T Haas; Bart Staels
Journal:  Mol Metab       Date:  2020-10-01       Impact factor: 8.568

10.  Genetic Variants Associated with Non-Alcoholic Fatty Liver Disease Do Not Associate with Measures of Sub-Clinical Atherosclerosis: Results from the IMPROVE Study.

Authors:  Luigi Castaldo; Federica Laguzzi; Rona J Strawbridge; Damiano Baldassarre; Fabrizio Veglia; Lorenzo Vigo; Elena Tremoli; Ulf de Faire; Per Eriksson; Andries J Smit; Jiri Aubrecht; Karin Leander; Matteo Pirro; Philippe Giral; Alberto Ritieni; Giovanni Di Minno; Anders Mälarstig; Bruna Gigante
Journal:  Genes (Basel)       Date:  2020-10-22       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.